Clinical trials: Lung Fibrosis Interstitial
Idiopathic Pulmonary Fibrosis
A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
This is a Phase 2, randomized, placebo controlled, multi-center study in subjects with mild to moderate IPF. Eligible subjects will be randomized to receive placebo or ENV-101 as a daily oral dose for 12 consecutive weeks of…
- Trial name
- NCT04968574
- Testing
- taladegib
- Where
- 24 sites in Australia, Canada and 3 more
- Volunteers
- 41 people
- Sponsor
- Endeavor Biomedicines, Inc.
Pulmonary Fibrosis
Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)
Primary objective of this study is to investigate the long-term tolerability and safety profile of BIBF 1120 on top of pirfenidone treatment in patients with Idiopathic Pulmonary Fibrosis who have completed a prior clinical trial…
- Trial name
- NCT01417156
- Testing
- Nintedanib, Pirfenidoneone
- Where
- 4 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
This is an 6 month multi-centre, prospective, randomized, placebo controlled, double blind clinical trial followed by conversion of each arm to active nintedanib for an additional 6 months comparing the effect of nintedanib 150mg…
- Trial name
- NCT01979952
- Testing
- Nintedanib
- Where
- 25 sites in United States, Canada and 1 more
- Volunteers
- 113 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis (IPF)
Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This study is open to people with idiopathic pulmonary fibrosis (IPF) . They can only take part if they have completed treatment in a previous study with a medicine called HSK44459.
- Trial name
- IPF (NCT07019090)
- Testing
- HSK44459
- Volunteers
- 120 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Idiopathic Pulmonary Fibrosis
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are 40 years and older. The purpose of this study is to find out whether a medicine called pirfenidone changes the amount of a medicine called BI 1015550…
- Trial name
- NCT06241560
- Testing
- BI 1015550, Pirfenidone
- Where
- 3 sites in United States, Georgia
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib
GSK3915393 is a new medicine which is being developed for a chronic lung disease called Idiopathic Pulmonary Fibrosis (IPF). This is a healthy participant study which has two parts.
- Trial name
- NCT06625489
- Testing
- Nintedanib, GSK3915393
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Idiopathic Pulmonary Fibrosis
Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001
Idiopathic pulmonary fibrosis (IPF) is a condition where the lungs are damaged and scarred with unknown reason, making breathing becomes increasingly difficult..
- Trial name
- NCT05657184
- Testing
- REGEND001
- Where
- 3 sites in China
- Volunteers
- 12 people
- Sponsor
- Regend Therapeutics
Idiopathic Pulmonary Fibrosis
Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada
This is a multi-center, non-interventional study to assess and describe course and outcomes in patients diagnosed with Idiopathic Pulmonary Fibrosis (IPF) who are treated with Esbriet (pirfenidone) in Canada, by measuring and…
- Trial name
- NCT02552849
- Testing
- No intervention
- Where
- 26 sites in Canada
- Volunteers
- 305 people
- Sponsor
- Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis (IPF)
A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
This study is a multicentre, randomised, double-blind, placebo-controlled, adaptive design clinical trial to evaluate the efficacy and safety of TDI01 suspension in the treatment of idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT07464912
- Testing
- TDI01
- Where
- China
- Volunteers
- 508 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Idiopathic Pulmonary Fibrosis
A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
This study assesses the tolerability of a single dose of gefapixant (AF-219) in participants with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT02477709
- Testing
- Gefapixant
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Idiopathic Pulmonary Fibrosis
A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.
The purpose of this study is to evaluate safety, tolerability, PK and immunogenicity of SV001 compare to placebo in Chinese healthy adult volunteers.
- Trial name
- NCT06267183
- Testing
- SV001
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Shanghai Synvida Biotechnology Co.,Ltd.
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
The study consists of 2 parts: Part A is a randomized, multiple-dose, double-blind, placebo-controlled sequential dose escalation study to evaluate GS-6624 in subjects with Idiopathic Pulmonary Fibrosis (IPF) and was completed in…
- Trial name
- NCT01362231
- Testing
- GS-6624
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Gilead Sciences
Idiopathic Pulmonary Fibrosis
To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers
An open label study to evaluate drug-drug interactions between HEC585 and Pirfenidone or Nintedanib in healthy volunteers
- Trial name
- NCT05383131
- Testing
- HEC585, Pirfenidone, Nintedanib
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Healthy Subjects
A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.
The study is intended to quantify the effect of co-administration and staggered dosing of AZD5055 and nintedanib on exposures of nintedanib in healthy participants.
- Trial name
- NCT05644600
- Testing
- Nintedanib, AZD5055
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
Adults 18 years of age and older or above legal age with lung fibrosis related to systemic autoimmune rheumatic disease can participate in this study.
- Trial name
- NCT06806592
- Testing
- Nerandomilast
- Where
- 153 sites in United States, Australia and 14 more
- Volunteers
- 414 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis (IPF)
Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
A multicenter, parallel, randomized, placebo (double-blind) and pirfenidone (open-label) controlled Phase III clinical trial to evaluate the efficacy and safety of HEC585 in patients with idiopathic pulmonary fibrosis (IPF)
- Trial name
- NCT07082842
- Testing
- HEC585, Pirfenidone
- Where
- China
- Volunteers
- 472 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Study RIN-PF-303 is a multinational study designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
- Trial name
- TETON-2 (NCT05255991)
- Testing
- Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
- Where
- 108 sites in Argentina, Australia and 14 more
- Volunteers
- 597 people
- Sponsor
- United Therapeutics
Healthy Participants
A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants
This is a study in healthy participants designed to assess the effect of multiple doses of itraconazole, gemfibrozil, or carbamazepine on the drug levels of a single-dose of BMS-986278.
- Trial name
- NCT05932303
- Testing
- BMS-986278, Itraconazole, Gemfibrozil
- Where
- Canada
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis (IPF)
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF…
- Trial name
- ASPIRE (NCT06588686)
- Testing
- Buloxibutid
- Where
- 104 sites in United States, Argentina and 12 more
- Volunteers
- 378 people
- Sponsor
- Vicore Pharma AB
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Caucasian Adult Males
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of SRN001 in healthy adult volunteers.
- Trial name
- NCT07407543
- Testing
- SRN001, 0.9% sodium chloride (normal saline)
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- siRNAgen Therapeutics Inc.